Gregory B. Lesinski - Concepedia

Author

Gregory B. Lesinski

Also Known As

G B Lesinski, G. B. Lesinski, G. Lesinski, G.B. Lesinski, Gregory B Lesinski, Gregory B. Lesinski, Gregory B. Lesinski B. Lesinski, Gregory Brian Lesinski, Gregory Lesinski, J. Brandon Dixon

462

Publications

8.1K

Citations

H-Index

Concepts

All Affiliations

The Ohio State University Emory University The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Cancer Genetics (United States)The Ohio State University Wexner Medical Center

About

Gregory B. Lesinski is an author at The Ohio State University specializing in medicine, immunology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	44	2.7K
2	Engineering	2	2	73
3	Public Health	2	2	107
4	Biomedical Engineering	2	2	73
5	Health Sciences	1	1	84

Gregory B. Lesinski

104

Publications

6.7K

Citations

H-Index

Page 1

	Year	Citations
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer Thomas A. Mace, Reena Shakya, Jason R. Pitarresi, Gut	2016	524
Pancreatic Cancer-Associated Stellate Cells Promote Differentiation of Myeloid-Derived Suppressor Cells in a STAT3-Dependent Manner Thomas A. Mace, Zeenath Ameen, Amy Collins, Cancer Research ImmunologyPathologyCancer BiologyTumor BiologyMyeloid Neoplasia	2013	393
β-Blockers and Survival among Danish Patients with Malignant Melanoma: A Population-Based Cohort Study Stanley Lemeshow, Henrik Toft Sørensen, Gary Phillips, Cancer Epidemiology Biomarkers & Prevention	2011	202
Enhanced bioavailability of lycopene when consumed as <i>cis</i>‐isomers from <i>tangerine</i> compared to red tomato juice, a randomized, cross‐over clinical trial Jessica L. Cooperstone, Robin A. Ralston, Kenneth M. Riedl, Molecular Nutrition & Food Research	2015	195
Myeloid-Derived Suppressor Cell Inhibition of the IFN Response in Tumor-Bearing Mice Bethany L. Mundy-Bosse, Gregory B. Lesinski, Alena Cristina Jaime‐Ramirez, Cancer Research	2011	187
Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment Sobeyda B. Gomez-Chou, Agnieszka Świdnicka‐Siergiejko, Niharika Badi, Cancer Research	2017	166
Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma Anne M. Noonan, Matthew R. Farren, Susan Geyer, Molecular Therapy	2016	150
A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells Li Lin, Stephanie Deangelis, Elizabeth Foust, Molecular Cancer	2010	148
A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant Melanoma Kimberly A. Varker, Jennifer E. Biber, Cheryl Kefauver, Annals of Surgical Oncology Metastatic Malignant MelanomaMedicineMelanomaImmunologyCancer Treatment	2007	142
The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse Gregory B. Lesinski, Mirela Anghelina, Jason M. Zimmerer, Journal of Clinical Investigation	2003	139

Page 1